Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Epistaxis is a major factor negatively affecting quality of life in patients with hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease). Optimal treatment for HHT-related epistaxis is uncertain.



To determine whether topical therapy with any of 3 drugs with differing mechanisms of action is effective in reducing HHT-related epistaxis.



The North American Study of Epistaxis in HHT was a double-blind, placebo-controlled randomized clinical trial performed at 6 HHT centers of excellence. From August 2011 through March 2014, there were 121 adult patients who met the clinical criteria for HHT and had experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3.0. Follow-up was completed in September 2014.



Patients received twice-daily nose sprays for 12 weeks with either bevacizumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d), or placebo (0.9% saline).



The primary outcome was median weekly epistaxis frequency during weeks 5 through 12. Secondary outcomes included median duration of epistaxis during weeks 5 through 12, Epistaxis Severity Score, level of hemoglobin, level of ferritin, need for transfusion, emergency department visits, and treatment failure.



Among the 121 patients who were randomized (mean age, 52.8 years [SD, 12.9 years]; 44% women with a median of 7.0 weekly episodes of epistaxis [interquartile range {IQR}, 3.0-14.0]), 106 patients completed the study duration for the primary outcome measure (43 were women [41%]). Drug therapy did not significantly reduce epistaxis frequency (P = .97). After 12 weeks of treatment, the median weekly number of bleeding episodes was 7.0 (IQR, 4.5-10.5) for patients in the bevacizumab group, 8.0 (IQR, 4.0-12.0) for the estriol group, 7.5 (IQR, 3.0-11.0) for the tranexamic acid group, and 8.0 (IQR, 3.0-14.0) for the placebo group. No drug treatment was significantly different from placebo for epistaxis duration. All groups had a significant improvement in Epistaxis Severity Score at weeks 12 and 24. There were no significant differences between groups for hemoglobin level, ferritin level, treatment failure, need for transfusion, or emergency department visits.



Among patients with HHT, there were no significant between-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency.



clinicaltrials.gov Identifier: NCT01408030.
Division of Cardiovascular Medicine and Pediatric Cardiology, Utah HHT Center of Excellence, University of Utah, Salt Lake City2George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, Utah.
Kevin J
KJ
Whitehead
Oregon Sinus Center, Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland.
Nathan B
NB
Sautter
Division of Interventional Radiology, Department of Radiology, UCLA HHT Center of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California.
Justin P
JP
McWilliams
Division of Pulmonary and Critical Care, Washington University School of Medicine, St Louis, Missouri.
Murali M
MM
Chakinala
Division of Pulmonary and Critical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Christian A
CA
Merlo
Department of Biostatistics and Epidemiology, Augusta University, Augusta, Georgia.
Maribeth H
MH
Johnson
Division of Pulmonary and Critical Care Medicine, Augusta University, Augusta, Georgia.
Melissa
M
James
O'Brien Pharmacy, Mission, Kansas.
Eric M
EM
Everett
Cure HHT, Monkton, Maryland.
Marianne S
MS
Clancy
Toronto HHT Program, Division of Respirology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada12Keenan Research Centre and Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
Marie E
ME
Faughnan
Department of Physiology and Functional Genomics, University of Florida, Gainesville.
S Paul
SP
Oh
Department of Ophthalmology, Children's Mercy Hospital, Kansas City, Missouri.
Scott E
SE
Olitsky
Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Reed E
RE
Pyeritz
Division of Pulmonary and Critical Care Medicine, Augusta University, Augusta, Georgia.
James R
JR
Gossage
D000281:Administration, Intranasal; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D001803:Blood Transfusion; D004311:Double-Blind Method; D004844:Epistaxis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*; D014148:Tranexamic Acid / Q000008:administration & dosage; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000933:Antifibrinolytic Agents; D000068258:Bevacizumab; D014148:Tranexamic Acid